Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001919722 | SCV002165124 | benign | Greig cephalopolysyndactyly syndrome; Pallister-Hall syndrome | 2022-08-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003247115 | SCV003944375 | uncertain significance | Inborn genetic diseases | 2023-04-24 | criteria provided, single submitter | clinical testing | The c.1159T>C (p.F387L) alteration is located in exon 8 (coding exon 7) of the GLI3 gene. This alteration results from a T to C substitution at nucleotide position 1159, causing the phenylalanine (F) at amino acid position 387 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005042474 | SCV005666136 | uncertain significance | Greig cephalopolysyndactyly syndrome; Pallister-Hall syndrome; Polysyndactyly 4; Polydactyly, postaxial, type A1 | 2024-05-07 | criteria provided, single submitter | clinical testing |